Pharmacotherapy of age-related macular degeneration

Bibliography

• Wang JJ, Rochtchina E, Lee AJ, et al. Ten year incidence and progression of age-related maculopathy the Blue Mountains Eye Study. Ophthalmol 2007;114(1):92-8
   PubMed Web of Science ®Google Scholar
• Van Leeuwen R, Klaver CC, Vingerling JR, et al. The risk and natural course of age-related maculopathy follow up at 612 years in the Rotterdam Study. Arch Ophthalmol 2003;121(4):519-26
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-31
   PubMed Web of Science ®Google Scholar
• Tap Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. TAP Report 1. Arch Ophthalmol 1999;117:1329-45
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-45
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group: Areds report no. 8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for advanced age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-36
   PubMed Web of Science ®Google Scholar
• Chong EW, Wong TY, Kreis AJ, et al. Dietary antioxidants and primary prevention of age related macular degeneration systematic review and meta-analysis. BMJ 2007;335(7623):755
   PubMed Web of Science ®Google Scholar
• Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad Sci USA 2005;102(20):7227-32
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter III R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age related macular degeneration. Science 2005;308:419-21
   PubMed Web of Science ®Google Scholar
• Hageman GS, Hancox LS, Taiber AJ, et al. Amd Clinical Study Group: Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med 2006;38(8):592-604
   PubMed Web of Science ®Google Scholar
• Janssen BJ, Halff EF, Lambris JD, et al. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem 2007;282(40):29241-247
   PubMed Web of Science ®Google Scholar
• Nilsson B, Larsson R, Hong J, et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood 1998;92(5):1661-7
   PubMed Web of Science ®Google Scholar
• Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP Report No 2. Arch. Ophthalmol 2001;119:198-207
   Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-60
   PubMed Web of Science ®Google Scholar
• Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1(2):182-93
   PubMed Web of Science ®Google Scholar
• Gottsch JD, Pou S, Bynoe LA, et al. Hematogenous photosensitization. A mechanism for the development of age-related macular degeneration. Invest Ophthalmol Vis Sci 1990;31:1674-82
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham JR, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Gonzales CR. VEGF Inhibition Study In Ocular Neovascularization Clinical Trial Group: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005;25:815-27
   PubMed Web of Science ®Google Scholar
• Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85(4):425-30
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin N Am 2006;19(3):361-72
   PubMedGoogle Scholar
• Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year Anchor results. Am J Ophthalmol 2007;144(6):850-7
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145(2):239-48
   PubMed Web of Science ®Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-83
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-8
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511
   PubMed Web of Science ®Google Scholar
• Thompson JT, Small interfering RNA (Cand5) for the treatment of subfoveal CNV. In AAO Annual Meeting, 2006
   Google Scholar
• Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 2006;13(3):225-34
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452(7187):591-7
   PubMed Web of Science ®Google Scholar
• Wen R, Zhao I, Liu Y, et al. VEGF trap induces significant regression of existing choroidal neovascularization (CNV). Invest Ophthalmol Vis Sci 2005;46: E-Abstr. 5307
   Google Scholar
• Nguyen QD, Shah SM, Hafiz G, et al. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522
   PubMed Web of Science ®Google Scholar
• Nguyen QD. For The Clear-It 1 Investigators: A randomized comparison of the safety, tolerability, and bioactivity study of two dose levels of intravitreal VEGF trap in patients with neovascular age-related macular degeneration. Presented at the Retina Society Annual Scientific Meeting, Boston; 2007
   Google Scholar
• Speicher MA, Danis RP, Criswell M, et al. Pharmacologic therapy for diabetic retinopathy. Expert Opin Emerg Drugs 2003;8(1):239-50
   PubMedGoogle Scholar
• Takahashi H, Obata R, Tamaki Y. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. J Ocul Pharmacol Ther 2006;22(4):213-8
   PubMed Web of Science ®Google Scholar
• Saishin Y, Lima Silva R, Callahan K, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44(11):4989-93
   PubMed Web of Science ®Google Scholar
• Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and age-related down regulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995;15(7 Part 1):4992-5003
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum Gene Ther 2006;17(2):167-76
   PubMed Web of Science ®Google Scholar
• Perrin RM, Konopatskaya O, Qiu Y, et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005;48(11):2422-7
   PubMed Web of Science ®Google Scholar
• Lima Silva R, Kachi S, et al. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp Eye Res 2006;83(5):1260-7
   PubMed Web of Science ®Google Scholar
• Heeschen C, Weis M, Aicher A, et al. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 2002;110(4):527-36
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004;8(6):551-64
   PubMed Web of Science ®Google Scholar
• Dejneka NS, Kuroki AM, Fosnot J, et al. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 2004;10:964-72
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Schloetzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3 and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80
   PubMed Web of Science ®Google Scholar
• Debefve E, Pegaz B, Van Den Bergh H, et al. Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne (R), in the CAM model. Angiogenesis 2008;11(3):235-43
   PubMed Web of Science ®Google Scholar
• Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46
   PubMed Web of Science ®Google Scholar
• Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142:95-104
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer DS, Ciulla TA, et al. And The Focus Study Group: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration year 1 results of the focus study. Arch Ophthalmol 2006;124:1532-42
   PubMed Web of Science ®Google Scholar
• Kaiser PK. for the Veritas Study Group. Verteporfin therapy in combination with pegaptanib or triamcinolone for wet AMD. 12-month study results. In AAO Annual Meeting, 2007
   Google Scholar